Suppr超能文献

相似文献

1
Health economic assessment: a methodological primer.
Int J Environ Res Public Health. 2009 Dec;6(12):2950-66. doi: 10.3390/ijerph6122950. Epub 2009 Nov 27.
2
Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Value Health. 2014 Jan-Feb;17(1):5-14. doi: 10.1016/j.jval.2013.08.2291. Epub 2013 Dec 13.
4
Improving the usefulness of budget impact analyses: a U.S. payer perspective.
Value Health. 2014 Jan-Feb;17(1):3-4. doi: 10.1016/j.jval.2013.09.007.
5
Resource modelling: the missing piece of the HTA jigsaw?
Pharmacoeconomics. 2015 Mar;33(3):193-203. doi: 10.1007/s40273-014-0228-9.
6
Discounting and decision making in the economic evaluation of health-care technologies.
Health Econ. 2011 Jan;20(1):2-15. doi: 10.1002/hec.1612. Epub 2010 May 12.
8
Budget impact analysis.
Epidemiol Serv Saude. 2017 Apr-Jun;26(2):421-424. doi: 10.5123/S1679-49742017000200020.
9
Spanish recommendations on economic evaluation of health technologies.
Eur J Health Econ. 2010 Oct;11(5):513-20. doi: 10.1007/s10198-010-0244-4. Epub 2010 Apr 20.
10
Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine.
Pharmacoeconomics. 2017 Jan;35(1):5-13. doi: 10.1007/s40273-016-0482-0.

引用本文的文献

1
Barriers and Enablers of Value-Based Procurement in Dutch Healthcare Providers.
Int J Health Policy Manag. 2025;14:8514. doi: 10.34172/ijhpm.8514. Epub 2025 May 28.
2
What are the costs associated with nausea and vomiting in pregnancy and hyperemesis gravidarum? A systematic review.
BMC Pregnancy Childbirth. 2025 Aug 1;25(1):807. doi: 10.1186/s12884-025-07921-5.
3
Socioeconomic inequality in financial hardship in accessing quality healthcare services in Ethiopia: a community-based cross-sectional study.
Front Public Health. 2025 Mar 26;13:1484671. doi: 10.3389/fpubh.2025.1484671. eCollection 2025.
7
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling.
Pharmacoeconomics. 2024 Nov;42(11):1255-1266. doi: 10.1007/s40273-024-01414-7. Epub 2024 Aug 6.

本文引用的文献

2
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.
Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78. doi: 10.1586/14737167.8.2.165.
3
Methodological issues in the monetary valuation of benefits in healthcare.
Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):717-27. doi: 10.1586/14737167.3.6.717.
4
Health utility estimation.
Expert Rev Pharmacoecon Outcomes Res. 2002 Apr;2(2):99-108. doi: 10.1586/14737167.2.2.99.
5
Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature.
Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):353-64. doi: 10.1586/erp.09.35.
6
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
Can J Clin Pharmacol. 2009 Summer;16(2):e273-81; discussion e282-4. Epub 2009 May 13.
7
Does preventive care save money? Health economics and the presidential candidates.
N Engl J Med. 2008 Feb 14;358(7):661-3. doi: 10.1056/NEJMp0708558.
9
The increasingly complex fourth hurdle for pharmaceuticals.
Pharmacoeconomics. 2007;25(9):727-34. doi: 10.2165/00019053-200725090-00002.
10
Endometriosis: cost estimates and methodological perspective.
Hum Reprod Update. 2007 Jul-Aug;13(4):395-404. doi: 10.1093/humupd/dmm010.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验